WHO: Remdesivir Does Not Substantially Affect COVID-19 Patient Mortality

Despite the hopes of an anxious world, and the pronouncements of high-profile individuals like President Donald Trump, Gilead Sciences' (NASDAQ:GILD) remdesivir is apparently not a game-changer for individuals afflicted with COVID-19.

That is the finding of the World Health Organization (WHO), which in its Solidarity clinical trial was studying the effects of four treatments, including Gilead's repurposed antiviral drug, on hospitalized COVID-19 patients. Passages from the study were quoted by the Financial Times in an article published Thursday. That article stressed that the study has not been peer-reviewed yet.